Weight-loss drug use in kids surged after doctors' recommendation
Why it matters: The findings from a review of more than 310,000 patients' health records add fuel to the debate over what age is too young for Wegovy and other GLP-1s.
While the heavily touted drugs offer opportunities to reduce the prevalence of childhood obesity, more studies are needed about the safety of newer versions in order to make informed decisions, the researchers from health data company Truveta and Harvard Medical School wrote.
What they found: Prescribing GLP-1s for weight management in youths ages 8 to 17 increased 65% immediately and another 5% per month following the Academy of Pediatrics guideline release.
Nutritional counseling showed a smaller, more gradual rise.
The diabetes drug metformin was the most prescribed medication overall, but its use declined over time while use of semaglutide — the active ingredient in Ozempic and Wegovy— increased substantially, from 2.5% of patients before the guidelines to 26.8%.
Despite concerns about overuse, rates of drug therapy in kids and adolescents remained low, with fewer than 10% of patients using anti-obesity medications, according to a separate study.
The big picture: Prescribing decisions generally appear to be cautious, with treatments most often targeted at adolescents with more severe obesity, said Tricia Rodriguez, lead author and director of applied research at Truveta.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
2 hours ago
- Los Angeles Times
Lawmakers press FDA to target knockoff weight-loss drug
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartis an lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. Muller writes for Bloomberg.
Bloomberg
9 hours ago
- Bloomberg
Lawmakers Press FDA to Target Compounded, Fake Weight-Loss Drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year.
Yahoo
10 hours ago
- Yahoo
Semaglutide improves brain-related injury patients' outcomes
GLP-1R agonist semaglutide, also known as Ozempic or Wegovy, has been making headlines for its potential in its original market - the treatment of Type 2 diabetes - for its weight loss effects and benefits in other metabolic disorders, and for its possible expansions into new therapeutic areas. Most recently, results from different studies have suggested that semaglutide may improve patient outcomes following brain haemorrhage or stroke. GlobalData estimates that semaglutide's benefits may be connected to a reduction of inflammation in the body and brain. As mentioned in GlobalData's report: GLP-1R Agonist - Label Expansions/Drug Repurposing: Market Overview, Ozempic is currently in Phase II trials for acute ischaemic stroke. Other GLP-1R agonists and combination therapies are in clinical development for other neurological conditions, and many academic studies are currently focusing on the potential use of GLP-1R agonists in stroke to reduce complications and the risk of recurrence altogether. In July 2025, new results have emerged from three studies investigating the use of semaglutide in stroke and brain haemorrhage patients. A study by the University of Wisconsin-Madison revealed that the chance of surviving after a stroke was higher in patients on semaglutide, and death from stroke was more frequent in the patient group not on a GLP-1R agonist. Another study by the same university examining a US nationwide sample of hospital records found an association between the use of GLP-1R agonists and a reduction in stroke complications. A third study by the University of Texas Medical Branch in Galveston suggested that semaglutide use was linked to a reduced risk of side effects, seizures, future recurrence and death after brain haemorrhage and stroke. The SELECT trial has demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its benefits in stroke patients. Furthermore, the occurrence of stroke is linked to metabolic health, inflammation and obesity, so an improvement in these factors can benefit patients likely to experience a stroke or who have done so in the past. According to key opinion leaders interviewed by GlobalData, the potential of GLP-1R agonists in brain diseases seems to be based on their anti-inflammatory action. Indeed, GLP-1R agonists are known to improve insulin sensitivity and reduce insulin resistance, and it seems that this translates to the brain too, as these molecules can cross the blood-brain barrier. Cerebrovascular conditions such as stroke and brain hemorrhage appear to benefit from both the cardiovascular benefits and cerebral anti-inflammatory health benefits associated with GLP-1R agonists' use, on top of the improvement in overall health. Therefore, GLP-1R agonists may successfully penetrate not one but multiple neurological diseases markets, if their effects are proven to be significant and worth the cost of these medicines. "Semaglutide improves brain-related injury patients' outcomes" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
